Pharmacogenomics in Cancer Therapeutics

Y. W.Francis Lam, Stuart A. Scott

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

With increased knowledge of molecular abnormalities in pathways associated with tumorigenesis, drug development within the oncology discipline has over the last decade mostly shifted from nonspecific cytotoxic agents to targeted therapies. Together with their companion diagnostic tests that allow identification of suitable patients for particular therapeutic agents, targeted anticancer therapy usher in a whole new era of precision therapy for patients with specific types of cancer. In addition to somatic mutations within tumors, genetic variabilities in drug response and/or toxicity are also potential factors that could account for differences in response to anticancer drug therapy. In this brief chapter, the role of pharmacogenomics in cancer therapy is presented focusing on some specific applications.

Original languageEnglish (US)
Title of host publicationPharmacogenomics
Subtitle of host publicationChallenges and Opportunities in Therapeutic Implementation
PublisherElsevier
Pages123-132
Number of pages10
ISBN (Electronic)9780128126264
DOIs
StatePublished - Jan 1 2018

Keywords

  • Pharmacogenomics
  • Precision oncology
  • predictive biomarkers
  • Prognostic
  • Targeted therapies

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Pharmacogenomics in Cancer Therapeutics'. Together they form a unique fingerprint.

Cite this